- Home
- PHGE vs ACXP Comparison
PHGE vs ACXP Comparison
Compare PHGE & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHGE
- ACXP
- Stock Information
- Founded
- PHGE 2015
- ACXP 2017
- Country
- PHGE Israel
- ACXP United States
- Employees
- PHGE N/A
- ACXP N/A
- Industry
- PHGE Biotechnology: Pharmaceutical Preparations
- ACXP Biotechnology: Pharmaceutical Preparations
- Sector
- PHGE Health Care
- ACXP Health Care
- Exchange
- PHGE Nasdaq
- ACXP Nasdaq
- Market Cap
- PHGE 26.5M
- ACXP 31.4M
- IPO Year
- PHGE N/A
- ACXP 2021
- Fundamental
- Price
- PHGE $0.49
- ACXP $1.30
- Analyst Decision
- PHGE Strong Buy
- ACXP Strong Buy
- Analyst Count
- PHGE 2
- ACXP 1
- Target Price
- PHGE $22.50
- ACXP $12.00
- AVG Volume (30 Days)
- PHGE 159.9K
- ACXP 97.1K
- Earning Date
- PHGE 11-14-2024
- ACXP 11-12-2024
- Dividend Yield
- PHGE N/A
- ACXP N/A
- EPS Growth
- PHGE N/A
- ACXP N/A
- EPS
- PHGE N/A
- ACXP N/A
- Revenue
- PHGE N/A
- ACXP N/A
- Revenue This Year
- PHGE N/A
- ACXP N/A
- Revenue Next Year
- PHGE N/A
- ACXP N/A
- P/E Ratio
- PHGE N/A
- ACXP N/A
- Revenue Growth
- PHGE N/A
- ACXP N/A
- 52 Week Low
- PHGE $0.49
- ACXP $1.18
- 52 Week High
- PHGE $8.55
- ACXP $5.28
- Technical
- Relative Strength Index (RSI)
- PHGE 21.78
- ACXP 12.41
- Support Level
- PHGE $0.56
- ACXP $1.18
- Resistance Level
- PHGE $0.79
- ACXP $1.73
- Average True Range (ATR)
- PHGE 0.10
- ACXP 0.12
- MACD
- PHGE -0.02
- ACXP -0.05
- Stochastic Oscillator
- PHGE 0.00
- ACXP 16.67
About PHGE BiomX Inc. COmmon Stock
BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. BX004 is its therapeutic phage product candidate under development for chronic pulmonary infections caused by Pseudomonas aeruginosa, or P. aeruginosa, a main contributor to morbidity and mortality in patients with CF.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.